NCT02504788
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 84 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must be planning to undergo whole brain radiation therapy (WBRT)
Exclusions: Patients with more than three brain metastases; Patients with brain metastases greater than 4 cm; Patients with clinical suspicion of leptomeningeal spreading; Patients with a history of prior radiation therapy
https://ClinicalTrials.gov/show/NCT02504788